Medtronic touts 3-year Heli-FX EndoAnchor registry study data

November 16, 2018 By Fink Densford Leave a Comment

Medtronic (NYSE:MDT) today released three-year data from the Anchor registry study of its Heli-FX EndoAnchor system, touting that it indicated the system is safe, efficient and durable in treating patients with complex aortic abdominal aneurysm anatomy, specifically those with hostile aortic neck anatomies.

Results from the trial were presented by co-principal investigator Dr. William Jordan of the Emory University School of Medicine at the 45th Annual Symposium of Vascular and Endovascular Issues in New York, the Fridley, Minn.-based company said.

“Hostile aortic necks are frequently seen in clinical practice and have historically presented challenges for physicians treating patients through an endovascular approach. With these data, we are continuing to validate that by using Heli-FX in these challenging cases, we have the ability to successfully treat this critical patient population and expand applicability of EVAR to those with complex aortic anatomies,” Dr. Jordan said in a prepared statement.

The registry includes data from 800 AAA patients treated with the Heli-FX in combination with Medtronic, Gore, Cook Medical and Jotek grafts, the company said. The majority of patients received EndoAnchor implants prophylactically, while a smaller group in the registry received them following a previously failed endovascular repair treatment or therapeutic revision.

Data in the presentation came from patients eligible for clinical and imaging follow-ups at three years. Patients in the prophylactic group had short, hostile neck anatomies with median neck lengths of 11.2mm, while those in the therapeutic group had an average of 10.2mm neck length, Medtronic said.

At three years, results indicated a 1.7% rate of Type Ia endoleaks for patients in the prophylactic cohort, with a 2.4% rate for the therapeutic revision arm. Positive sac stability and regression despite hostile anatomy was observed at 96.5% in the prophylactic group at three years and 80% in the therapeutic revision group.

Patients in the prophylactic group experienced a 98.7% rate of freedom from secondary procedures to treat Type Ia endoleaks based on Kaplan-Meier estimates and a 98.3% rate of freedom from aneurysm related mortality based on the same estimates. Patients in the revision group had rates of 86.3% freedom from secondary procedures to treat Type Ia endoleaks and a 91.1% rate of freedom from aneurysm related mortality, Medtronic said.

“With Heli-FX, our focus continues to be on improving the lives of patients with complex aortic disease by broadening applicability of endovascular repair to patients who have traditionally been challenging to treat. These data further validate the use of EndoAnchor fixation as a long-term solution that enhances outcomes and durability in patients with complex aortic anatomies,” aortic biz GM & VP John Farquhar said in a press release.

Earlier this week, the Children’s National Health System announced that it was collaborating with Medtronic to develop a miniature pacemaker intended for use with infants.

Only a Few More Days to Register for the most anticipated conference of the winter!

DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.

Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.

REGISTER NOW

Use code LASTCHANCE to save an additional 20%.

Strata Skin Sciences adds license for excimer laser vitiligo treatment
Strata Skin Sciences(NSDQ:SSKN) said it has reached an agreement with an “internationally acclaimed health institution” giving Strata an exclusive license to treat vitiligo using its Xtrac excimer laser. In a novel treatment for vitiligo, the excimer laser incrementally increases the light emitted in the UVB range to restore pigmentation to skin areas affected with vitiligo.… […]
5 questions you need to ask when engaging a medical device outsourcer
A methodical, structured process is key when lining up a medical device outsourcer. That was one of the top takeaways from a webinar that Medical Design & Outsourcing held with top officials at contract manufacturing giant Integer last week. “It’s time well spent to do your due diligence, to dig into these details, and to… […]
In2Bones intros ‘see-through’ implant for flat feet
Orthopedic surgical device developer In2Bones announced the global launch of its “see-through” PitStop implant for children and adults with flat feet. One of the most common foot deformities, flat-foot often starts during adolescence and continues into adulthood. In2Bones (Memphis, Tenn.) developed the PitStop subtalar implant to restore the stability of a patient’s arch during the walking process. Get… […]
Olympus fined $85 million in duodenoscope case; former exec faces prison
Olympus (TYO:7733) and a former senior executive in Japan have pleaded guilty in Newark, N.J., to failing to file required adverse event reports involving infections connected to duodenoscopes, and to continuing to sell the devices in the United States despite those failures, the Justice Department announced. Tokyo-based Olympus and Hisao Yabe, 62, both entered guilty pleas before… […]
Cardinal Health launches supply chain solution
Cardinal Health has launched a supply chain automation solution that is designed to address the challenges in the operating room. The single health system-wide platform allows hospitals to streamline OR processes, reduce costs and improve efficiency with real-time inventory visibility and prescriptive analytics. The system also offers real-time insights and wrap-around logistics. “We recognized that… […]
Millar wins expanded CE Mark for Mikro-Cath pressure catheter
Millar has received a CE Mark approval expansion for its Mikro-Cath Pressure Catheter. The expansion now includes airway and intra-compartmental pressure measurements. The new expansion will give physicians the opportunity to make improvements in respiratory care while delivering a continuous monitoring technique for measuring compartment pressure and diagnosing acute compartment syndrome at onset. Mikro-Cath can… […]
How technology can ensure MDR compliance – and better business performance
The mid-2020 deadline for MDR compliance is getting closer. Here’s how companies can use technology to ensure compliance. Melonie Warfel, Veeva Systems As we enter 2019, the mid-2020 deadline for the Medical Device Regulation (MDR) is getting closer. It will change the rules for medical device manufacturers and distributors operating in Europe, replacing the current… […]
FDA grants breakthrough status to joint Merck-Bayer AI program
Merck and Bayer have been granted FDA Breakthrough Device Designation for the collaborative Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Artificial Intelligence Pattern Recognition software. CTEPH can be difficult to diagnose because its symptoms are similar to asthma and chronic obstructive pulmonary disease symptoms. CTEPH affects five people per million annually worldwide. Computed tomography pulmonary angiography and… […]
Nexxt Spine launches Saxxony posterior cervical spine system
Nexxt Spine has received FDA 510(k) clearance and has commercially launched its Saxxony Posterior Cervical Thoracic System. The system is designed to stabilize cervical (C1 to C7) and thoracic (T1 to T3) spinal segments through posterior screw fixation. “The Saxxony System adds a robust posterior complement to our well received anterior cervical fixation offering as… […]
MICROMO launches miniature gearheads with integrated leadscrews for linear actuation
MICROMO has launched a new series of linear actuators that feature standard gearheads with an integrated leadscrew that allow for any rotary motor to produce linear micro motion. The company suggests that the gearheads with integrated leadscrew offer a cost advantage to engineers and also provide a more compact motion solution when compared to conventional… […]
How Reggie Groves reinvented Medtronic’s atrial fibrillation biz
Reva Medical (ASX:RVA) CEO Reggie Groves got her start in the medical device industry at medtech titan Medtronic. In her upcoming keynote interview at DeviceTalks West, Groves will discuss how that experience has shaped her as a leader and an innovator. Here’s a preview: When Reggie Groves joined Medtronic (NYSE:MDT) in 2002, she didn’t know very much about… […]